Add Company
Join Now

StrataDx Revenue and Competitors

License our Company Data API

Boston, MA USA

Location

N/A

Total Funding

Medical Offices

Industry

Estimated Revenue & Valuation

  • StrataDx's estimated annual revenue is currently $15.6M per year.(i)
  • StrataDx's estimated revenue per employee is $243,000

Employee Data

  • StrataDx has 64 Employees.(i)

StrataDx's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Director Anatomic PathologyReveal Email/Phone
3
HR ManagerReveal Email/Phone
4
DermatopathologistReveal Email/Phone
5
Specimen ProcessorReveal Email/Phone
6
Histology TechnicianReveal Email/Phone
7
Histology tech Lead TechReveal Email/Phone
8
Associate PathologistReveal Email/Phone
9
Account ExecutiveReveal Email/Phone
10
Client Strategy Specialist IReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.1M1330%N/AN/A
#2
$14.3M599%N/AN/A
#3
$7.6M350%N/AN/A
#4
$28.9M1077%N/AN/A
#5
$0.1M10%N/AN/A
#6
$133.3M395-3%N/AN/A
#7
$30M111-12%N/AN/A
#8
$5.3M28-3%N/AN/A
#9
$5.3M284%N/AN/A
#10
$5.3M280%N/AN/A
Add Company

What Is StrataDx?

For nearly three decades, StrataDxâ„¢ has been a leading anatomic pathology laboratory dedicated to providing physicians, patients and hospitals with unrivaled diagnostic services. Our board-certified pathologists, including distinguished thought leaders Drs. Lisa Cohen and Terence Harrist are committed to providing the most reliable timely diagnosis of cancer and other diseases every day by combining an academic approach with outstanding customer service. StrataDx offers the latest in surgical pathology, cytology, immunofluorescence, molecular diagnostic and prognostic techniques and a comprehensive test menu for a variety of clinical specialties.

keywords:N/A

N/A

Total Funding

64

Number of Employees

$15.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.6M647%N/A
#2
$18.9M643%N/A
#3
$5.8M648%N/A
#4
$13.1M648%N/A
#5
$19.3M65-3%N/A